Edoardo Crimini MD

Medical Oncologist and PhD candidate. University of Milan, European Institute of Oncology

[G Curigliano MD PhD @curijoey]

🇮🇹 The ROME trial marks a milestone for Italy’s precision oncology platform: 6 years of dedication, 40 centers, 1,794 patients sequenced. A national effort to bring genomics to the heart of cancer care. @myESMO @IEOufficiale @LaStatale

[Andrea Botticelli @DottBotticelliA]

The impact of concordance of molecular profile on tissue and liquid biopsy on response to target therapy and immunotherapy : a posthoc analysis of the Rome trial !A novel challange ? @AACR @curijoey @BenWestphalen @VivekSubbiah @oncologiaroma

[Carlos Torrado @CarlosTorradoMD]

Excited to present our poster on the results of one of Dr. Yap’s Investigator-Initiated Trials at @AACR , with additional insights from single-cell analysis performed by Dr. Haymaker’s team. @MDAndersonNews

https://t.co/rGi67x6hHt

[Edoardo Crimini MD @CriminiMd]

🖥️🎯 Happy to present at #AACR2025 the benchmark testing of our academical, independent and budget-friendly trial matcher OncoSolver (OS), that may improve the workflow of patient referrals to trials. Time to start its clinical validation at @IEOufficiale @curijoey

[Edoardo Crimini MD @CriminiMd]

Last days to vote for @myESMO presidential election! I strongly support Giuseppe Curigliano! @curijoey @PTarantinoMD

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

I echo 🇮🇹 the AIOM and fully support Giuseppe Curigliano (@curijoey) for ESMO President 2027-28.

I urge all medical oncologists & @myESMO members worldwide to vote for Prof Curigliano.

Every vote counts‼️

https://t.co/OhtmP1IecL @IEOufficiale

[Edoardo Crimini MD @CriminiMd]

I'm proud to support the candidacy of my mentor, Prof. Curigliano, for the ESMO presidential elections, now open! It's rare to find a person who is so dedicated to the professional and personal growth of their mentees. I can't imagine a better candidate for this role! @curijoey

[Paolo Tarantino @PTarantinoMD]

I’m excited to support @curijoey for the ESMO Presidential Elections!

A compassionate clinician and true leader in drug development, Giuseppe has trained an entire generation of young physicians, with a transformative impact in oncology.

Make sure to vote for him from May 28!

[Carmine Valenza @ValenzaCarmine]

A brilliant oncologist, a great mentor, and a continuous source of inspiration 🔥🔥🔥

Proud of @myESMO choice to candidate @curijoey as ESMO President

[Edoardo Crimini MD @CriminiMd]

@toninorudiger Cafone

[Edoardo Crimini MD @CriminiMd]

Such a honor to attend ESMO TAT 2024 with my fantastic mentors, @curijoey and Dr. Meric-Bernstam, TAT Honorary Award recipient for her contribution to precision oncology. Congrats also to @BoscoloLuca_ for the best abstract award in the Molecular profiling applications section!

[Paolo Tarantino @PTarantinoMD]

The @IEOufficiale #CuriglianoLab team and alumni at #ESMO23 - a wonderful, progressively expanding group of young oncologists, now spread across the 🌍 but united by friendship, passion, and a common, great mentor. So lucky and proud to be part of it.

[Vivek Subbiah, MD @VivekSubbiah]

🚨Hot off the press👉Super thrilled to share our paper 👉Variant of allele frequency: a decision-making tool in precision oncology? published in @CellCellPress journal @trendscancer !
👉An absolute delight to collaborate with the amazing @curijoey & his terrific team @darioT_ @CriminiMd among many others @oncoalert @PTarantinoMD #PrecisionMedicine 🎯🧬 @SarahCannonDocs
✅A great pre-read before #ESMO23 and #MAP23 meetings
https://t.co/GIZZ5vHNaV

[Paolo Tarantino @PTarantinoMD]

NGS allows to match pts to trials, but only if these are accessible. In our latest @OncJournal article led by @CriminiMd, we analyze geographical accessibility to NGS-informed trials in 🇮🇹, finding heterogenous availability, but a trend toward improvement.
https://t.co/XsoKDT2s4d

[Liliana Ascione @lilli_ash]

Predicting response to ADCs: still a long road ahead.

Check our review just published in @OncJournal https://t.co/m423b8NCoo

@curijoey @CriminiMd @darioT_ @CarmenCriscit @antoniomarraMD @IEOufficiale

[Edoardo Crimini MD @CriminiMd]

📢 On EJC our comprehensive analysis of current phase I clinical trials, led by Dr Repetto. Many drugs may be affected by the "me too" phenomenon and few are against novel targets. Pairing TCGA data revealed underserved histologies @curijoey @alexdrilon https://t.co/BMDafkHGTU

[Edoardo Crimini MD @CriminiMd]

Amazing experience at the Italian Summit on Precision Medicine in Rome! It was a pleasure to listen to such outstanding lectures and a honour to be invited to give a talk on Molecular Tumor Boards! Thank so much to Prof Curigliano and Prof Marchetti for the opportunity! @curijoey

[Edoardo Crimini MD @CriminiMd]

Just out on European Journal of Cancer our report of @IEOufficiale's molecular tumor board, confirming the essential role played by MTBs in expanding opportunities and improving outcomes of cancer patients. Thanks to all the fantastic team! @curijoey
https://t.co/gQoxZ7M1cX

[Pier Paolo Berton Giachetti @PierPaoloBG]

Thrilled to be here all together #sabcs2022

[Paolo Tarantino @PTarantinoMD]

MTBs help translating the complexity of cancer genomics into therapeutic indications. They are only useful, however, if the indication leads to the administration of a treatment. In this review led by @CriminiMd we discuss the challenges of this process.
https://t.co/lBEDwRA2pD

[Edoardo Crimini MD @CriminiMd]

@darioT_ @curijoey @LaStatale @IEOufficiale Thank you Dario! We are glad that the jury understood the importance to have a comprehensive tool capable of really helping cancer patients to obtain targeted therapies and accessing clinical trials!

[Edoardo Crimini MD @CriminiMd]

I am really proud to share a pic of the win of our project #OncoSolver, a precision medicine software, today at #AI4GOV Startup Contest! Thank you #PoliHub for the opportunity! We will do our best to put it in practice under #EY coaching! @curijoey @LaStatale @IEOufficiale